As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

财务业绩 - 第四季度收入增长12%至599亿美元[2] - 第四季度非GAAP营业利润增长14%至6.05亿美元，非GAAP每股收益增长29%至1.84美元[2] - 2024财年经营现金流和调整后自由现金流均创历史新高，分别为38亿美元和39亿美元[2] - 2024财年第四季度收入为598.67亿美元，同比增长12%[29] - 2024财年全年收入为2268.27亿美元，同比增长11%[29] - 2024财年第四季度毛利为18.82亿美元，同比增长5%[29] - 2024财年全年毛利为74.14亿美元，同比增长8%[29] - 2024财年第四季度营业利润为4.01亿美元，同比大幅增长[30] - 2024财年全年营业利润为12.43亿美元，同比增长65%[30] - 2024财年第四季度净利润为2.35亿美元，去年同期为净亏损[34] - 2024财年全年净利润为8.52亿美元，去年同期为3.30亿美元[34] - 公司2024财年总收入为226,912百万美元，同比增长11%[70] - 公司2024财年非GAAP营业利润为2,414百万美元，同比增长16%[61] - 公司2024财年非GAAP每股收益为7.53美元，同比增长29%[61] - 公司2023财年总收入为19,700百万美元，同比增长6%[61] - 公司2023财年非GAAP营业利润为2,076百万美元，同比增长5%[61] - 公司2023财年非GAAP每股收益为5.85美元，同比增长15%[61] - 公司2024财年非GAAP调整后自由现金流为3,942百万美元[67][68] - 公司2023财年非GAAP调整后自由现金流为2,853百万美元[67] 分部业绩 - 医药及专科解决方案分部收入为556.08亿美元，同比增长13%[51] - 医药及专科解决方案分部利润为20.15亿美元，同比增长7%[55] - 医疗产品及分销分部收入为123.81亿美元，同比增长1%[54] - 医疗产品及分销分部利润为0.92亿美元[55] - 公司2024财年医药及专科解决方案分部收入为210,019百万美元，同比增长11%[70] - 公司2024财年医疗产品及分销分部收入为12,381百万美元，同比增长1%[70] - 2023财年第三季度制药及专业解决方案分部收入为46,500百万美元，同比增长14%[72] - 2023财年第三季度制药及专业解决方案分部利润为583百万美元，同比增长26%[73] - 2023财年第三季度GMPD分部亏损收窄至32百万美元[73] 非GAAP财务指标 - 非GAAP毛利率为18.82%，同比增长5%[57] - 非GAAP营业利润为6.05亿美元，同比增长14%[57] - 非GAAP每股收益为1.84美元，同比增长29%[57] - 公司使用非GAAP财务指标来评估内部业务表现，并向投资者提供补充指标[99] - 公司排除了一些项目(如LIFO费用、州阿片类药物评估费用、股东合作协议费用等)来计算非GAAP财务指标[99,100] - 公司提供了非GAAP调整后自由现金流作为补充指标，用于评估现金流变化和与同行比较[102] - 公司在提供未来展望时使用非GAAP指标,因为一些排除项目的发生时间和金额难以预测[103] - 公司提供了非GAAP指标的定义,包括计算方法和排除项目[104] 其他 - 2025财年非GAAP每股收益指引上调至7.55美元至7.70美元，此前为至少7.50美元[16] - 医疗产品与分销(GMPD)分部2025财年利润目标提高至约3亿美元，并计划在2026财年前创造至少5亿美元的短期价值[19] - 公司宣布与CVS Health合资成立Averon公司，专注于通过生物类似药品采购提高患者获取专科药品的可及性[20] - 公司宣布与Publix超市签订5年分销协议[20] - 公司开设了新的先进疗法解决方案创新中心，支持细胞和基因疗法的复杂处理要求[20] - 2024年6月30日现金及现金等价物为51.33亿美元，较上年同期增加26%[38] - 2024年6月30日存货净额为149.57亿美元，较上年同期减少7%[38] - 公司现金及等价物净增加/(减少)为13.87亿美元[48] - 期初现金及等价物为37.46亿美元，期末为51.33亿美元[48]

公司业绩预期 - Cardinal Health, Inc. (CAH) 预计在2024年8月14日开盘前发布第四季度财报 [1] - 分析师预计公司季度每股收益为$1.73，相比去年同期的$1.55有所增长 [2] - 预计季度营收为$58.64 billion，相比去年同期的$53.45 billion有所增长 [2] 股息和股价动态 - 公司于5月7日批准将季度股息从$0.5006增加到$0.5056 [2] - 公司股价在周二上涨1.9%，收盘价为$102.58 [2] 分析师评级 - Baird分析师Eric Coldwell维持“跑赢大盘”评级，并将目标价从$129提高到$130 [2] - Argus Research分析师David Toung维持“买入”评级，并将目标价从$120降低到$115 [2] - Wells Fargo分析师Stephen Baxter维持“减持”评级，并将目标价从$96降低到$94 [2] - UBS分析师Kevin Caliendo维持“买入”评级，并将目标价从$122提高到$125 [2] - Mizuho分析师Ann Hynes维持“中性”评级，并将目标价从$95提高到$104 [2]

Cardinal Health, Inc. (CAH) is scheduled to report fourth-quarter fiscal 2024 results on Aug 14, before the opening bell.In the last reported quarter, the company delivered an earnings surprise of 6.67%. CAH’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 12.91%.Q4 EstimatesFor the fiscal fourth quarter, the consensus mark for earnings is pegged at $1.72 per share, indicating an improvement of 10.9% from the prior-year quarter’s reported ...

Analysts on Wall Street project that Cardinal Health (CAH) will announce quarterly earnings of $1.72 per share in its forthcoming report, representing an increase of 11% year over year. Revenues are projected to reach $58.72 billion, increasing 9.9% from the same quarter last year.Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forec ...

The market expects Cardinal Health (CAH) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

文章核心观点 - 公司股价在最新市场收盘时达到99.52美元,较前一交易日上涨1.18%,超过标普500指数当日1.04%的涨幅 [1] - 公司股价在过去一个月内上涨1.53%,超过医疗行业0.21%的涨幅和标普500指数6.74%的下跌 [2] - 公司预计将于2024年8月14日发布财报,预计每股收益为1.72美元,同比增长10.97%;预计收入为587.2亿美元,同比增长9.86% [3] - 分析师对公司业务健康状况和盈利能力持乐观态度,上调了对公司的预测 [4][5] - 公司当前的市盈率为13.03倍,低于行业平均水平18.7倍,估值相对较低 [7][8] 行业分析 - 公司所属的医疗-牙科用品行业目前在250多个行业中排名靠后,位于底部20%区间 [9][10] - 该行业的平均市盈率增长比率为1.93倍,而公司的市盈率增长比率为1.08倍,低于行业平均水平 [8]

DNY59 CAH stock: unfavorable PEG ratio I last covered Cardinal Health (NYSE:CAH) stock a bit more than 3 months ago. As you can see from the chart below, my last article, titled "Cardinal Health: Solid Business But Overvalued", was published on April 18, 2024, and argued for a HOLD thesis on the stock. The holding rating was mainly based on the following considerations: Cardinal Health is overvalued, with a dividend yield lower than its historical average and a high P/E ratio. Growth projections for the ...

The latest trading session saw Cardinal Health (CAH) ending at $100.83, denoting a +0.57% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 1.08% for the day. Meanwhile, the Dow gained 0.75%, and the Nasdaq, a tech-heavy index, added 2.64%.Coming into today, shares of the prescription drug distributor had gained 3.85% in the past month. In that same time, the Medical sector gained 0.71%, while the S&P 500 lost 0.44%.Market participants will be closely foll ...

Cardinal Health (CAH) closed the latest trading day at $96.71, indicating a +0.91% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 2.32%. Elsewhere, the Dow saw a downswing of 1.25%, while the tech-heavy Nasdaq depreciated by 3.64%.The prescription drug distributor's shares have seen a decrease of 7.07% over the last month, not keeping up with the Medical sector's gain of 0.32% and the S&P 500's gain of 1.79%.Analysts and investors alike will be k ...